J&J Must Pay Basilea $130M Over License: Dutch Court
The Netherlands Arbitration Institute's award covers lost profits, other damages and interest, and is “immediately enforceable,” according to Basilea.
The two companies have sparred for years over ceftobiprole, designed to fight penicillin-resistant Streptococcus pneumoniae and serious skin infections like methicillin-resistant Staphylococcus aureus, the so-called superbug commonly known as MRSA.
Basilea granted Johnson &...
To view the full article, register now.